BWP
ERNA icon

Baldwin Wealth Partners’s Eterna Therapeutics ERNA Stock Holding History

Baldwin Wealth Partners’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-23
Closed -$8.97K – 486
2024
Q3 		$8.97K Hold
23
– – ﹤0.01% 811
2024
Q2 		$15.6K Hold
23
– – ﹤0.01% 496
2024
Q1 		$20.5K Hold
23
– – ﹤0.01% 486
2023
Q4 		$15.3K Sell
23
-2
-8% -$1.15K ﹤0.01% 531
2023
Q3 		$20.6K Hold
25
– – ﹤0.01% 507
2023
Q2 		$21.4K Hold
25
– – ﹤0.01% 526
2023
Q1 		$32.2K Hold
25
– – ﹤0.01% 482
2022
Q4 		$29.6K Buy
25
+20
+400% +$28.2K ﹤0.01% 492
2022
Q3 		$10K Hold
5
– – ﹤0.01% 519
2022
Q2 		$21K Hold
5
– – ﹤0.01% 466
2022
Q1 		$79K Hold
5
– – 0.01% 309
2021
Q4 		$161K Hold
5
– – 0.02% 218
2021
Q3 		$359K Sell
5
-1
-17% -$86.3K 0.04% 147
2021
Q2 		$795K Buy
+6
New +$864K 0.09% 83

Other funds holding ERNA

Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SCA
Sippican Capital Advisors Boston, Massachusetts $164M AUM 35.17% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baldwin Wealth Partners's ERNA Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Eterna Therapeutics (ERNA) in Q4 2024, closing a stake of 23 shares — an estimated $8.97K sold.

Baldwin Wealth Partners first reported a position in ERNA in Q2 2021 and held it in 14 quarters. The position peaked at $795K in Q2 2021. 18 funds tracked by Wall St. Rank hold ERNA as of Q4 2024.

  • Baldwin Wealth Partners reported no remaining Eterna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Baldwin Wealth Partners sold 23 Eterna Therapeutics shares in Q4 2024, an estimated $8.97K.
  • Baldwin Wealth Partners first reported a position in Eterna Therapeutics in Q2 2021 and held it in 14 quarters.
  • Baldwin Wealth Partners's Eterna Therapeutics position peaked at $795K in Q2 2021.
  • 18 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.